Pharmaceuticals and Diagnostics

Click here to view our Pharmaceuticals and Diagnostics professionals

Drawing on our strengths in biomedical and chemical matters, we have prosecuted, licensed, and litigated a wide variety of patents in the pharmaceutical and diagnostics fields, including such technologies as:

  • medical diagnostics
  • target discovery
  • high-throughput screening
  • combinatorial chemistry
  • drug-delivery systems
  • therapeutic small molecules
  • drug and antibody assay devices, methods, and reagents.

 

Pharmaceutical patents, and other biotechnology patents generally, are part of our core biotechnology work.

P: 312.913.2104
F: 312.913.0002
P: 312.935.2369
F: 312.913.0002
P: 312.913.2140
F: 312.913.0002
Senior Patent Agent
P: 312.913.3357
F: 312.913.0002
P: 312.913.2130
F: 312.913.0002
P: 312.913.2146
F: 312.913.0002
P: 312.913.3330
F: 312.913.0002
P: 312.913.3345
F: 312.913.0002
P: 312.913.3317
F: 312.913.0002
P: 312.913.3352
F: 312.913.0002
P: 312.913.2109
F: 312.913.0002
P: 312.913.2121
F: 312.913.0002
P: 312.913.3332
F: 312.913.0002
P: 360.379.6514
F: 312.913.2557
P: 312.913.2117
F: 312.913.0002
P: 312.913.2143
F: 312.913.0002
P: 312.913.3315
F: 312.913.0002
P: 312.913.3333
F: 312.913.0002
P: 312.913.2135
F: 312.913.0002
P: 312.913.3366
F: 312.913.0002
P: 312.913.2116
F: 312.913.0002
P: 312.913.2106
F: 312.913.0002
P: 312.935.2371
F: 312.913.0002
P: 312.913.2123
F: 312.913.0002
P: 312.935.2372
F: 312.913.0002
Associate
P: 312.913.2125
F: 312.913.0002
P: 312.913.3393
F: 312.913.0002
P: 312.913.3346
F: 312.913.0002
P: 312.913.2129
F: 312.913.0002
P: 312.913.2101
F: 312.913.0002
P: 312.913.3344
F: 312.913.0002
P: 312.913.2126
F: 312.913.0002
P: 312.913.3302
F: 312.913.0002
P: 312.935.2370
F: 312.913.0002
P: 312.913.2145
F: 312.913.0002
P: 312.913.3349
F: 312.913.0002
P: 312.913.2118
F: 312.913.0002
P: 312.935.2366
F: 312.913.0002
P: 312.913.2133
F: 312.913.0002
P: 312.913.3356
F: 312.913.0002
P: 312.913.2136
F: 312.913.0002
P: 312.913.3348
F: 312.913.0002
P: 312.935.2379
F: 312.913.0002
P: 312.913.3368
F: 312.913.0002
P: 312.913.3301
F: 312.913.0002
P: 312.913.2114
F: 312.913.0002
Associate
P: 312.913.2142
F: 312.913.0002
P: 312.913.2132
F: 312.913.0002

Upcoming Events

February 23, 2016
MBHB Partner Dr. Kevin Noonan Is a Featured Presenter at this ACI-Sponsored Program
February 24, 2016
March 16, 2016
MBHB Partner Daniel Boehnen and Bristows LLP Partner Edward Nodder Are the Featured Co-Presenters
May 25, 2016
MBHB Partner Dr. Kevin Noonan Is the Featured Presenter at this ALA-Sponsored Session

Past Event

January 21, 2016
MBHB Attorneys Michael Borella, Ph.D., Kevin Noonan, Ph.D. and Donald Zuhn, Jr., Ph.D. Are the Featured Co-Presenters
December 10-11, 2015
MBHB Partner Bradley Hulbert Is a Featured Presenter
December 9, 2015
December 3-4, 2015
MBHB Partners Anthoula Pomrening and James Suggs Are Featured Co-Presenters at this Management Forum-Sponsored Conference  
November 17, 2015

Publications

Fall 2015 (snippets)
According to a recent court ruling, Costco sold counterfeit diamond engagement rings bearing the Tiffany name and confused relevant consumers by using the word “Tiffany” in display case signage. The court rejected Costco’s fair use defense and assertion that Tiffany’s trademarks were invalid because they sought to prevent others from using the word “Tiffany” as a generic description of a type of ring setting. Under the ruling, Tiffany can now take Costco before a jury to seek damages, including recovery of Costco’s profits from the sale of the diamond rings and punitive damages.
Fall 2015 (snippets)
This is the perfect time and environment in which to take a close look at your trademark portfolio. It is the time to be thankful for your brand’s position in the market and the investments you have made into searching, registering, maintaining, and enforcing your trademarks. But it is also the time to set goals and develop plans to make better use of your trademark portfolios.
Fall 2015 (snippets)
Under the Federal Trade Commission (“FTC”) Act, advertising must be truthful and non-deceptive, advertisers must have evidence to back up their claims, and advertisements cannot be unfair. An advertisement is deceptive if it misleads reasonable consumers and is material to a consumer’s decision to purchase a product. An advertisement is unfair if it causes substantial unavoidable injury that is not outweighed by its benefit to consumers.
Fall 2015 (snippets)
Trademarks are valuable tools for businesses since they allow a trademark holder to identify and distinguish its goods from those manufactured or sold by others. However, there are many issues to be aware of when seeking trademark protection.
Summer 2015 (snippets)
In an effort to simplify production issues for our clients – and to ensure that they themselves are in compliance with the EU and Swiss Privacy Laws on protection of personal information – MBHB has obtained certification under the U.S.-EU Safe Harbor Framework and the U.S.-Swiss Safe Harbor Framework. This certification process allows clients peace of mind when transferring documents and other materials that may contain personal data from the EU and/or Switzerland to the United States.
Summer 2015 (snippets)
In the highly fractured Amgen v. Sandoz decision, the Federal Circuit, in part, concluded that the Biologics Price Competition and Innovation Act (“BPCIA”) patent resolution procedure was not mandatory, leaving open the distinct possibility that no biosimilar applicant will ever use the new biosimilar approval pathway.
Close
Generate a PDF of your page(s)
Clear
Close
Remove
Page has been queued
An error has occurred
Add
Added to queue
View
Confirm Delete All Message
No Items in Packet Message
To add a page, select Add. To view the package, select View.
false
http://www.mbhb.com/services/xpqServiceDetail.aspx?xpST=ServiceDetail&service=298&pdf=yes
a[href='javascript:packetBuilderSingleClick(document.title);']